Biotech Rising

In 2014, the top six best-selling drugs will be biotech products, says EvaluatePharma, a healthcare analysis company. Of the top 100, they say biotech drugs will account for half. Evaulate predicts that the number one drug in five years will be Roche's Avastin, followed by Abbott's Humira, Roche's Rituxan, Wyeth's Enbrel, Sanofi-Aventis' Lantus, and Roche's Herceptin, according to Reuters.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

New Mexico is re-doing its proposed science education standards after criticism, the Associated Press reports.

Agbio executives say gene editing will speed up breeding efforts, according to the Wall Street Journal.

La Trobe University's Jenny Graves has won the $250,000 Prime Minister's Prize for Science, the Guardian reports.

In Cell this week: post-treatment changes to melanoma genome, multi-omics analysis of muscle-invasive bladder cancer, and more.